XML 20 R8.htm IDEA: XBRL DOCUMENT v3.3.1.900
Acquisition of Dr. Organic
3 Months Ended
Dec. 31, 2015
Acquisition of Dr. Organic  
Acquisitions

2. Acquisition of Dr. Organic

        In December 2015, NBTY (2015) Limited ("NBTY (2015)"), a private limited company incorporated in England and Wales and an indirect subsidiary of Alphabet Holding Company, Inc. ("Holdings"), our parent company, and Holland & Barrett Group Limited ("H&B"), a company incorporated in England and Wales and an indirect subsidiary of Holdings, completed the purchase Dr. Organic, pursuant to which NBTY (2015) acquired all of the ordinary shares of Dr. Organic, a manufacturer, marketer and distributor of a broad line of naturally-inspired personal care products.

        The purchase price for the ordinary shares of Dr. Organic was £53,384 (approximately $80,519), paid in (i) cash of £33,384 (approximately $50,353) (the "cash consideration"), (ii) loan notes in an aggregate principal amount of £20,000 (approximately $30,166) (the "completion loan notes") issued by NBTY (2015) to the sellers, which mature 18 months after issuance and are redeemable at any time after six months at the option of the holders, (iii) 399,000 class B ordinary shares, par value £0.01 (the "rollover shares"), issued by NBTY (2015) to the sellers and (iv) 222,000 class C ordinary shares, par value £0.01, issued by NBTY (2015) to certain of the sellers at a premium of £0.04 each (which will be redeemed by NBTY (2015) for £0.05 18 months after issuance). Holders of the rollover shares may require us to repurchase them for an amount based on the future earnings of Dr. Organic and its subsidiaries (the "repurchase amount"), which amount is payable, at the election of holders, in cash or through the issuance of loan notes by NBTY (2015) with terms similar to the completion loan notes. To the extent the holders do not exercise their put right, we will have the right to call the rollover shares at the repurchase amount. The put is exercisable for thirty days commencing in January 2019 and the call is exercisable thirty days after the expiration of the put for a period of thirty days.

        The following allocation of the purchase price is preliminary and based on information available to the Company's management at the time the consolidated financial statements were prepared. Accordingly, the allocation is subject to change and the impact of such changes could be material. The allocation of the purchase price is as follows:

                                                                                                                                                                                    

Fair value of consideration:

 

 

 

 

Cash

 

$

50,353

 

Completion loan notes at fair value

 

 

28,931

 

Redeemable non-controlling interest

 

 

104,224

 

Less:

 

 

 

 

Settlement of payables due to Dr. Organic

 

 

(6,032

)

Cash and cash equivalents acquired

 

 

(5,342

)

​  

​  

 

 

$

172,134

 

​  

​  

​  

​  

Allocated to:

 

 

 

 

Assets:

 

 

 

 

Accounts receivable

 

$

7,922

 

Inventories

 

 

22,474

 

Other current assets

 

 

2,045

 

Property, plant, and equipment

 

 

276

 

Intangibles assets

 

 

70,438

 

Liabilities:

 

 

 

 

Accounts payable

 

 

(7,175

)

Accrued expenses and other current liabilities

 

 

(3,059

)

Deferred income taxes

 

 

(15,186

)

​  

​  

Net assets acquired

 

 

77,735

 

​  

​  

Goodwill

 

$

94,399

 

​  

​  

​  

​  

        The fair values of the net assets acquired were determined using discounted cash flow analyses and estimates made by management. The purchase price was allocated to intangible assets as follows: $94,399 to goodwill, which is non-amortizable and is not deductible for income tax purposes, approximately $46,000 to tradenames, which are amortizable over 10-15 years and approximately $25,000 to customer relationships, which are amortizable over 25 years. Acquisition costs for Dr. Organic amounted to approximately $5,000. The acquisition of Dr. Organic is expected to expand our operations in the Consumer Products Group segment in the distribution of natural personal care products. Additionally, we believe that we can leverage our existing distribution channels of our Consumer Products Group, which is the primary driver behind the excess of the purchase price paid over the fair value of the assets and liabilities acquired. Results since the acquisition to date and pro forma information with respect to Dr. Organic have not been provided as this acquisition was not considered material to our operations.